To include your compound in the COVID-19 Resource Center, submit it here.

Stopping the invasion

How targeting the IRF3 pathway could prevent GBM recurrence

A team from the Netherlands Cancer Institute (NKI) has identified a network of extracellular matrix proteins that drives glioblastoma invasiveness and a master switch -- interferon regulatory factor 3 (IRF3) -- that can turn it off. The group believes combining IRF3 activation with standard of care could prevent recurrence.

In a Cell Reports study in July, the NKI team, led by Olaf van Tellingen and René

Read the full 668 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE